vimarsana.com

Latest Breaking News On - Lung cancer conference - Page 1 : vimarsana.com

First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.

Dr Curran on Developing Strategies for Stage III NSCLC Management

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC of the Lung

The FDA has granted a fast track designation to BI 764532 for use as a therapeutic option in patients with advanced or metastatic DLL3-expressing large-cell neuroendocrine carcinoma of the lung who experienced disease progression after treatment with 1 or more lines of therapy, including platinum-based chemotherapy.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.